immunovant_logoV7_RGB.png
Immunovant to Present at the Stifel 2021 Virtual Healthcare Conference
November 12, 2021 12:18 ET | Immunovant
NEW YORK, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today...
immunovant_logoV7_RGB.png
Immunovant Reports Financial Results for the Quarter Ended September 30, 2021
November 05, 2021 07:30 ET | Immunovant
NEW YORK, Nov. 05, 2021 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today...
immunovant_logoV7_RGB.png
Immunovant to Participate in Roivant R&D Day 2021
September 27, 2021 08:00 ET | Immunovant
NEW YORK, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today...
immunovant_logoV7_RGB.png
Immunovant Appoints Renee Barnett as Chief Financial Officer
September 15, 2021 07:00 ET | Immunovant
Ms. Barnett brings a wealth of financial experience to ImmunovantExpands executive leadership team as Immunovant plans to return to the clinic across multiple indications NEW YORK, Sept. 15, 2021 ...
immunovant_logoV7_RGB.png
Immunovant Reports Financial Results for the Quarter Ended June 30, 2021
August 09, 2021 06:30 ET | Immunovant
NEW YORK, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today...
immunovant_logoV7_RGB.png
Immunovant to Report Financial Results for Quarter Ended June 30, 2021
August 06, 2021 16:22 ET | Immunovant
NEW YORK, Aug. 06, 2021 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today...
immunovant_logoV7_RGB.png
Immunovant Receives $200 Million Strategic Investment from Roivant Sciences
August 02, 2021 07:30 ET | Immunovant
Proceeds will fund continued development of IMVT-1401 in multiple indications NEW YORK, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company...
immunovant_logoV7_RGB.png
Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter and Fiscal Year Ended March 31, 2021
June 01, 2021 07:31 ET | Immunovant
Immunovant plans to resume clinical development of IMVT-1401 in Myasthenia Gravis (MG) and Warm Autoimmune Hemolytic Anemia (WAIHA) as well as initiate two additional mid-to-late stage studies in the...
immunovant_logoV7_RGB.png
Immunovant Reports Financial Results for the Quarter and Nine Months Ended December 31, 2020
February 16, 2021 08:00 ET | Immunovant
NEW YORK, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases, today...
immunovant_logoV7_RGB.png
Immunovant Announces Voluntary Pause in Clinical Dosing of IMVT-1401
February 02, 2021 06:30 ET | Immunovant
NEW YORK, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases, today...